Literature DB >> 12811546

Nitroheterocyclic drugs with broad spectrum activity.

W Raether1, H Hänel.   

Abstract

The group of biologically active nitroheterocyclic compounds includes various 5- and 2-nitroimidazoles and 5-nitrofurans, which can be used as therapeutic agents against a variety of protozoan and bacterial (anaerobic) infections of humans and animals. The current status in the the treatment of giardiasis, trichomoniasis, balantidiasis, histomoniasis, and amebiasis (including infections due to opportunistic amebas) is presented. The most relevant drugs (benznidazole, furazolidone, metronidazole, misonidazole, nifurtimox, nimorazole, nitazoxanide, ornidazole, secnidazole, and tinidazole) are characterized with regard to their chemical, chemotherapeutic, toxicological, pharmacokinetic, and pharmacological properties, including the mechanism of action and resistance in certain parasitic protozoa.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12811546     DOI: 10.1007/s00436-002-0754-9

Source DB:  PubMed          Journal:  Parasitol Res        ISSN: 0932-0113            Impact factor:   2.289


  42 in total

1.  The anti-trypanosome drug fexinidazole shows potential for treating visceral leishmaniasis.

Authors:  Susan Wyllie; Stephen Patterson; Laste Stojanovski; Frederick R C Simeons; Suzanne Norval; Robert Kime; Kevin D Read; Alan H Fairlamb
Journal:  Sci Transl Med       Date:  2012-02-01       Impact factor: 17.956

2.  Characterization of a melamino nitroheterocycle as a potential lead for the treatment of human african trypanosomiasis.

Authors:  Federica Giordani; Annamaria Buschini; Alessandro Baliani; Marcel Kaiser; Reto Brun; Michael P Barrett; Claudia Pellacani; Paola Poli; Ian H Gilbert
Journal:  Antimicrob Agents Chemother       Date:  2014-07-14       Impact factor: 5.191

3.  ANTIVIRAL COMPOUNDS IN THE PIPELINE TO TACKLE H1N1 INFLUENZA INFECTION.

Authors:  J H Beigel
Journal:  Drugs Future       Date:  2010-05       Impact factor: 0.148

Review 4.  Recent developments and future prospects in the treatment of visceral leishmaniasis.

Authors:  Shyam Sundar; Anup Singh
Journal:  Ther Adv Infect Dis       Date:  2016-04-22

Review 5.  Innovative Partnerships for the Elimination of Human African Trypanosomiasis and the Development of Fexinidazole.

Authors:  Philippe Neau; Heinz Hänel; Valérie Lameyre; Nathalie Strub-Wourgaft; Luc Kuykens
Journal:  Trop Med Infect Dis       Date:  2020-01-27

6.  Investigational drugs for visceral leishmaniasis.

Authors:  Shyam Sundar; Jaya Chakravarty
Journal:  Expert Opin Investig Drugs       Date:  2014-11-20       Impact factor: 6.206

7.  Microbiologic response to treatment of bacterial vaginosis with topical clindamycin or metronidazole.

Authors:  M N Austin; R H Beigi; L A Meyn; S L Hillier
Journal:  J Clin Microbiol       Date:  2005-09       Impact factor: 5.948

8.  A non-natural nucleoside with combined therapeutic and diagnostic activities against leukemia.

Authors:  Edward A Motea; Irene Lee; Anthony J Berdis
Journal:  ACS Chem Biol       Date:  2012-03-13       Impact factor: 5.100

9.  Genotoxicity revaluation of three commercial nitroheterocyclic drugs: nifurtimox, benznidazole, and metronidazole.

Authors:  Annamaria Buschini; Lisa Ferrarini; Susanna Franzoni; Serena Galati; Mirca Lazzaretti; Francesca Mussi; Cristina Northfleet de Albuquerque; Tânia Maria Araújo Domingues Zucchi; Paola Poli
Journal:  J Parasitol Res       Date:  2009-10-21

10.  Collateral effects of antibiotics: carbadox and metronidazole induce VSH-1 and facilitate gene transfer among Brachyspira hyodysenteriae strains.

Authors:  Thaddeus B Stanton; Samuel B Humphrey; Vijay K Sharma; Richard L Zuerner
Journal:  Appl Environ Microbiol       Date:  2008-03-21       Impact factor: 4.792

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.